Voyageur Pharmaceuticals Ltd. (VYYRF)

Voyageur Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is December - November.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 31, 2025	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020
Cost of Revenue	0.01	-	-	-	-	-
Gross Profit	-0	-	-	-	-	-
Selling, General & Admin	1.74	1.1	0.99	1.45	1.23	0.71
Operating Expenses	2.51	1.51	1.22	1.61	1.97	1.14
Operating Income	-2.51	-1.51	-1.22	-1.61	-1.97	-1.14
Other Non Operating Income (Expenses)	-0.61	-0.18	-0.12	-0.15	-0.08	-0
EBT Excluding Unusual Items	-3.12	-1.7	-1.35	-1.75	-2.05	-1.14
Gain (Loss) on Sale of Assets	-	-	-	-0.01	-	-
Asset Writedown	-0.01	-0.01	-0.05	-	-	-
Other Unusual Items	-	-	-0	0	-	-
Pretax Income	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14
Net Income	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14
Net Income to Common	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14
Shares Outstanding (Basic)	156	138	131	108	95	71
Shares Outstanding (Diluted)	156	138	131	108	95	71
Shares Change (YoY)	14.68%	5.46%	21.03%	13.89%	34.24%	22.58%
EPS (Basic)	-0.02	-0.01	-0.01	-0.02	-0.02	-0.02
EPS (Diluted)	-0.02	-0.01	-0.01	-0.02	-0.02	-0.02
Free Cash Flow	-2.71	-0.47	-1.17	-2	-2.09	-0.43
Free Cash Flow Per Share	-0.02	-0.00	-0.01	-0.02	-0.02	-0.01
EBITDA	-2.51	-1.51	-1.22	-1.6	-1.97	-0.98
D&A For EBITDA	0	0	0	0.01	0.01	0.15
EBIT	-2.51	-1.51	-1.22	-1.61	-1.97	-1.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.